Mr. Craig Millian reports

HLS ANNOUNCES REIMBURSEMENT FOR VASCEPA UNDER ALBERTA'S PROVINCIAL DRUG PLAN

HLS Therapeutics Inc. has entered into a product listing agreement (PLA) with the Province of Alberta for the listing and public reimbursement of Vascepa (icosapent ethyl). The PLA with Alberta Health is effective Aug. 1, 2024.

Under the terms of the PLA, Vascepa will be reimbursed as a special authority product by Alberta Health for the secondary prevention of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with established cardiovascular disease and elevated triglycerides.

"The PLA with Alberta Health will significantly improve access and reimbursement for Vascepa in Canada's fourth-largest province," said Craig Millian, chief executive officer of HLS. "Cardiovascular disease remains one of the leading causes of death in Canada, so, we are very pleased to now provide national coverage for Vascepa to more than 90 per cent of eligible Canadians covered by both public and private plans."

Approximately 12 per cent of all Canadians live in Alberta. As disclosed previously, HLS has achieved public reimbursement for Ontario, Quebec, British Columbia, Saskatchewan, New Brunswick, Northwest Territories, Veterans Affairs and the NIHB (non-insured health benefits) program for first nations and Inuit peoples.

ABOUT Vascepa (icosapent ethyl) capsules

Vascepa capsules are the first and only prescription treatment comprising solely the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. Vascepa was approved by Health Canada and added to Health Canada's Register of Innovative Drugs and benefits from data protection for a term of eight years as well as being the subject of multiple issued and pending patents based on its unique clinical profile. HLS in-licensed the exclusive rights to Vascepa for the Canadian market from Amarin Corp.

About HLS Therapeutics Inc.

Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage-development, commercial-stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong record of success in these therapeutic areas and at managing products in each of these life-cycle stages.

We seek Safe Harbor.